Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).
Azathioprine may leads to lower severe adverse events compared with methotrexate (low certainty).
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Azathioprine showed no clear difference in adverse events causing death or study drug discontinuation compared with methotrexate (low certainty).
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine and infliximab changes adverse events compared with infliximab (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with 5‐aminosalicylic acid (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with anti TNF‐α (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with placebo (low certainty).
Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).
Azathioprine or 6‐mercaptopurine may leads to higher adverse events compared with placebo (low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes adverse events compared with mesalazine or sulfasalazine (very low certainty).
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).